Payton v. Abbott Labs
Opinions
This case comes before the court on certification from the United States District Court for the District of Massachusetts of four principal and several subsidiary ques[542] tions involving Massachusetts tort law. See S.J.C. Rule 1:03, § 1, as amended, 382 Mass. 700 (1981).
The plaintiffs in the civil action in which these questions are certified seek redress for injuries allegedly caused by the prescription drug diethylstilbestrol (DES). They brought suit in the Federal District Court in April, 1976. In July, 1979, a judge of the Federal District Court conditionally certified the plaintiff class under Fed. R. Civ. P. 23 (c)(4)(A) to permit resolution of thirteen specific class-wide issues. Payton v. Abbott Labs, 83 F.R.D. 382, 386 (D. Mass. 1979). Several of these issues are factual; the four questions here certified involve issues of Massachusetts law which the judge believed “may be determinative of various aspects of this case and as to which it appears . . . that there is no controlling precedent” in the decisions of this court.
The questions are presented by the judge in the context of a motion to dismiss, based upon the plaintiffs’ allegations. The judge summarized those allegations as follows:
“The plaintiffs are all females whose mothers ingested a drug called diethylstilbestrol . . . while pregnant with the plaintiffs. DES was marketed by the defendants as a preventative for miscarriages, and was widely prescribed by physicians. DES is transmitted to the fetus, and has been identified as one cause of a relatively rare but extremely malignant cancer called clear-cell adenocarcinoma which attacks the reproductive organs of the female children of mothers who have ingested DES. DES has also been identified as one of the causes of more common benign changes in the female children’s reproductive organs, one of which is known as adenosis. The only corrective for clear-cell ade-nocarcinoma is timely radical surgery or radiation; if treatment is not successful the disease is likely to be fatal.
“Many of the plaintiffs have no symptoms of any of these conditions. As a result of their mothers’ ingestion of DES, these plaintiffs are statistically more likely to suffer one of several abnormalities of the reproductive organ than is the general population and are to a lesser degree more likely to [543] contract clear-cell adenocarcinoma.Footnotes
437 N.E.2d 171 (Payton v. Abbott Labs) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.